P Vittal, C Pulliam, C Goetz, J Jankovic, J Ramirez-Castaneda, D Heldman
18th International Congress of Parkinson’s Disease and Movement Disorders, Stockholm, Sweden, 2014
…
Blog Archives
Methodology for a Symptomatic Impact Study Using a Portable Essential Tremor Monitor to Direct Therapeutic Interventions
PRESS RELEASE: Great Lakes NeuroTechnologies Secures $1.7 Million to Develop Continuous Dyskinesia Monitoring Technology for Parkinson’s Disease
05 Mar 2013: Valley View, OH – Great Lakes NeuroTechnologies (GLNT) announced today that they are launching commercialization and clinical studies to validate a system for objective, continuous monitoring of dyskinesias associated with Parkinson’s disease. The study is being funded by a $1,743,051 Phase II Small Business Innovative Research grant from the National Institutes of Health (NIH),
…
PRESS RELEASE: GLNT Receives $1.5 Million to Further Technology for Assessing Bradykinesia Response to Novel Therapies in Parkinson’s Disease
08 AUG 2012: Valley View, OH – Great Lakes NeuroTechnologies [ http://www.glneurotech.com ] announced today that they have received $1.5 million in funding to commercialize a technology for Parkinson’s disease (PD) patients that will better assess motor symptoms in response to new deep brain stimulation (DBS) and pharmaceutical therapies.
…
Capturing Choreatic Dyskinesia Over Levodopa Dose Cycle in Parkinson’s Disease
T. Mera, Michelle Burack, MD, PhD, Frank Bonsignore, MS, J. Giuffrida, PhD
American Academy of Neurology 64th Annual Meeting, New Orleans, LA 2012
…
PRESS RELEASE: The University of Rochester and Great Lakes NeuroTechnologies launch new clinical study to develop ambulatory dyskinesia assessment system
Cleveland, OH – August 15, 2011 – Great Lakes NeuroTechnologies’ KinetiSense motion sensor technology will be used in a clinical study to capture and quantify dyskinesias (involuntary, irregular movements) caused by Parkinson’s disease (PD) medication. PD motor symptoms including tremor and bradykinesia are typically treated with levodopa.
…
